These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38821637)

  • 1. Molecular Pathology of Lung Cancer.
    Roy-Chowdhuri S
    Clin Lab Med; 2024 Jun; 44(2):137-147. PubMed ID: 38821637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pathology of Lung Cancer.
    Roy-Chowdhuri S
    Surg Pathol Clin; 2021 Sep; 14(3):369-377. PubMed ID: 34373089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts on the molecular pathology of non-small cell lung carcinoma.
    Fujimoto J; Wistuba II
    Semin Diagn Pathol; 2014 Jul; 31(4):306-13. PubMed ID: 25239274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future trends in non-small cell lung cancer biomarker testing: The American experience.
    VanderLaan PA; Roy-Chowdhuri S
    Cancer Cytopathol; 2020 Sep; 128(9):629-636. PubMed ID: 32885913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
    Kerr KM; Bibeau F; Thunnissen E; Botling J; Ryška A; Wolf J; Öhrling K; Burdon P; Malapelle U; Büttner R
    Lung Cancer; 2021 Apr; 154():161-175. PubMed ID: 33690091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
    DiBardino DM; Saqi A; Elvin JA; Greenbowe J; Suh JH; Miller VA; Ali SM; Stoopler M; Bulman WA
    Clin Lung Cancer; 2016 Nov; 17(6):517-522.e3. PubMed ID: 27378171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
    Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
    Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates in Lung Cancer Cytopathology.
    VanderLaan PA
    Surg Pathol Clin; 2018 Sep; 11(3):515-522. PubMed ID: 30190138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
    Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
    J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
    Canberk S; Engels M
    Virchows Arch; 2021 Jan; 478(1):45-57. PubMed ID: 33389149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Testing in Lung Cancer: Recommendations and Update.
    Borczuk AC
    Surg Pathol Clin; 2024 Jun; 17(2):307-320. PubMed ID: 38692813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement.
    Navani N; Butler R; Ibrahimo S; Verma A; Evans M; Doherty GJ; Ahmed S
    Lung Cancer; 2022 Oct; 172():142-153. PubMed ID: 36099709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.
    Prabhash K; Advani SH; Batra U; Biswas B; Chougule A; Ghosh M; Muddu VK; Sahoo TP; Vaid AK
    Adv Ther; 2019 Apr; 36(4):766-785. PubMed ID: 30864106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
    Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
    Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
    Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
    Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Ancillary Techniques in Pulmonary Cytopathology.
    Zhou F; Moreira AL
    Acta Cytol; 2020; 64(1-2):166-174. PubMed ID: 31013490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    J Mol Diagn; 2018 Mar; 20(2):129-159. PubMed ID: 29398453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.